Adjuvant MAGE-A3 Immunotherapy in Resected Non–Small-Cell Lung Cancer: Phase II Randomized Study Results

The MAGE-A3 protein is expressed in approximately 35% of patients with resectable non-small-cell lung cancer (NSCLC). Several immunization approaches against the MAGE-A3 antigen have shown few, but often long-lasting, clinical responses in patients with metastatic melanoma. A double-blind, randomize...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical oncology 2013-07, Vol.31 (19), p.2396-2403
Hauptverfasser:	VANSTEENKISTE, Johan, ZIELINSKI, Marcin, PERDEUS, Jakub, BONNET, Reiner, BASKO, Jazeps, JANILIONIS, Richard, PASSLICK, Bernward, TREASURE, Tom, GILLET, Marc, LEHMANN, Frédéric F, BRICHARD, Vincent G, LINDER, Albert, DAHABREH, Jubrail, GONZALEZ, Emilio E, MALINOWSKI, Wojciech, LOPEZ-BREA, Marta, VANAKESA, Tonu, JASSEM, Jacek, KALOFONOS, Haralabos
Format:	Artikel
Sprache:	eng
Schlagworte:	Adjuvants, Immunologic - therapeutic use Adult Aged Aged, 80 and over Antigens, Neoplasm - immunology Biological and medical sciences Cancer Vaccines - therapeutic use Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - immunology Carcinoma, Non-Small-Cell Lung - surgery Disease-Free Survival Double-Blind Method Europe Female Gene Expression Regulation, Neoplastic Humans Immunotherapy - methods Kaplan-Meier Estimate Lung Neoplasms - drug therapy Lung Neoplasms - immunology Lung Neoplasms - surgery Male Medical sciences Middle Aged Molecular Targeted Therapy - methods Multiple tumors. Solid tumors. Tumors in childhood (general aspects) Neoplasm Proteins - immunology Pneumology Recombinant Proteins - therapeutic use Treatment Outcome Tumors Tumors of the respiratory system and mediastinum
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!